CONTEXT: Splenic diffuse red-pulp small B-cell lymphoma is a rare disease, representing less than 1% of all non-Hodgkin lymphomas (NHL). This entity is characterized by involvement of bone marrow sinusoids and peripheral blood. The majority of cases are at an advanced stage when diagnosed. Its pathogenesis is still poorly understood. CASE REPORTS: We report on two patients with chronic non-replicating hepatitis B virus (HBV) who developed splenic diffuse red-pulp small B-cell lymphoma. Both of them were in stage IV at diagnosis and evolved with aggressive disease. Both of them achieved a complete response through chemotherapy, but one of them died due to infectious complications during bone marrow transplantation. The other decided not to undergo transplantation and continues not to show any evidence of disease today (three years after treatment). Some studies have shown a possible association between B-cell NHL and HBV. Nonetheless, the mechanism through which this oncogenic virus interacts with B-cell NHL is still poorly understood. HBV is lymphotropic and may insert into the host's genome, thus causing overexpression of oncogenes and downregulation of tumor suppressor genes. Therefore, chronic stimulation by HBV can increase B-cell proliferation, which promotes monoclonal expansion of these cells and results in malignancy. CONCLUSION: HBV may be implicated in the pathogenesis of this lymphoma, although no direct association between these two entities could be proved in the present study. Further investigations are necessary.
INTRODUCTION
Splenic diffuse red-pulp small B-cell lymphoma was recognized as a provisional entity in the 2008 update of the World Health Organization (WHO) classification. 1 This new WHO update recognized two categories of primary splenic lymphomas; splenic marginal-zone lymphoma (SMZL) and the provisional group of splenic B-cell lymphoma/leukemia unclassifiable (SLLU), that includes splenic diffuse red-pulp small B-cell lymphoma and hairy-cell leukemia variant (HCL-v). 1 The median age at which patients are diagnosed with splenic diffuse red-pulp small B-cell lymphoma is 72 years (range: 69-74 years), 2 and the disease is seen predominantly among males, with a male/female ratio of 2.4:1.
Splenic diffuse red-pulp small B-cell lymphoma is a rare disease and represents less than 1% of all non-Hodgkin lymphomas (NHL) and 10% of B-cell lymphomas that are described in postsplenectomy series. 1 This malignancy is characterized by diffuse infiltrate of monomorphic small to medium-sized B-cells with cytoplasmic villi, going into the red pulp of the spleen. The bone marrow sinusoids and peripheral blood are frequently involved.
Patients usually present with an advanced stage of disease when they are diagnosed. Peripheral lymph node involvement and B-symptoms are rarely reported and massive splenomegaly is common. 1 Splenic diffuse red-pulp small B-cell lymphomas have an indolent clinical course and there is no known standard treatment approach. So far, most of these patients have been treated with splenectomy. 3 The pathogenesis of this lymphoma is still poorly understood and no risk factors associated with its development have been described. Recent studies have shown an association between B-cell NHL and hepatitis B virus (HBV), but the mechanism through which this oncogenic virus results in chronic lymphoproliferative B-cell disorders is not clearly understood. To the best of our knowledge, there is no case report in the literature correlating HBV with splenic diffuse red-pulp small B-cell lymphoma. Here, we describe two cases of splenic diffuse red-pulp small B-cell lymphoma associated with chronic HBV infection.
CASE REPORTS

Case 1
A 62-year-old woman presented at our clinic complaining of weight loss, fever, night sweats and increasing abdominal size over the preceding two months. In her medical history, she reported having had rheumatoid arthritis, which was previously treated with chloroquine and methotrexate, and an untreated chronic non-replicating HBV infection (AntiHbC total +, AgHbe −, AntiHbe +, AgHbs +, AntiHbsAg -) with quantitative polimerase chain reaction (PCR) for HBV of 104 IU/ml (normal range of values: 20-170,000,000 IU/ml). Other viral serological tests for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) were negative. In her family history, her daughter had had a central nervous system (CNS) neoplasm, a 60-year-old brother had had prostate cancer and another 50-year-old brother had died of acute leukemia.
In her physical examination, she presented as emaciated and pale, with massive splenomegaly and no palpable hepatomegaly or peripheral lymphadenopathy. Computed tomography (CT) scans showed subtle hepatomegaly and greatly increased spleen size, with no lymphadenopathy (Figure 1) .
Laboratory tests showed normocytic and normochromic anemia (hemoglobin 8.8 g/dl, platelet count of 124 x 10 9 /l and total leukocyte count of 6.18 x 10 9 /l); 21% of the lymphoid cells had a high nuclear-to-cytoplasmic ratio, with loose chromatin, small clear nucleolus and thin cytoplasmic projections.
Immunophenotyping of peripheral blood cells showed that they Thus, integration of all these findings, i.e. lymphoproliferative malignancy of small B cells, diffuse infiltration of the spleen and primary from splenic red pulp, with exclusion criteria for "hairy cell" and its variant form, enabled the definitive accurate diagnosis of splenic diffuse red-pulp small B-cell lymphoma in both cases reported here.
We conducted a systematic search in the main electronic databases (PubMed, Google Scholar and Lilacs Library), to find articles relating to splenic diffuse red-pulp small B-cell lymphoma in association with hepatitis B infection. In order to make the search as wide as possible, no limits were applied regarding the date of publication, the language or the research design The most common finding in the bone marrow biopsies was predominance of intrasinusoidal lymphoid infiltration, some- Kanellis et al. 2 found p53 inactivation in all cases of splenic diffuse red-pulp small B-cell lymphoma, comprising either p53 mutation (2/4 cases) or anomalous p53 staining. Mollejo et al. 4 reported that TP53 abnormality was present in 2 out of 13 cases (15.3%): one of these patients showed disease progression and ultimately died of the disease. In the same way as described by these authors, one of our patients also had a p53 deletion and evolved to aggressive disease. Splenic diffuse red-pulp small B-cell lymphoma is an indolent lymphoma and patients can be maintained using a watchful waiting approach or may undergo splenectomy. 20 Another meta-analysis on 12 case-control studies, comprising 11 studies evaluating HBV infection in NHL and one study that had investigated NHL in HBV infection, reported that the OR of detecting HBV infection in lymphoma patients was 2.5 times higher than in controls. 21 These studies suggest a possible relationship between HBV and NHL. The pathogenic association is less well studied than relationships with HCV, but it appears to result from different HBVdriven events. 22 HBV is a hepatotropic virus and replicates within hepatocytes, but it can also cause lymphotropism for lymphocytes in the peripheral blood, bone marrow, spleen, lymph nodes, and thymus. [23] [24] [25] [26] This lymphotropism of HBV is a fundamental property favoring causality between HBV and B-cell malignancies.
Additionally, a study evaluating CD20 cell expression in the liver of HBsAg-positive and HBeAg-negative patients found that all of them were CD20-positive. 27 Wang et al. 28 found higher prevalence of HBeAg and anti-HBe in NHL cases than in controls, thus suggesting that viral replication may be required to support neoplastic proliferation. HBV integrates into the host genome and can lead to overexpression of cellular oncogenes or downregulation of tumor suppressor gene expression. Introduction of whole-genome sequencing identified several preferred sites for HBV integration, some of which have also been described in lymphomas, CCNE (cyclin E1) 29 and the PDGF receptor. 30 Also, the HBX protein transactivates cellular promoters and enhancers, including the binding site for NF-KB. 12 The HBX protein is involved in blocking p53-mediated apoptosis, which has been implicated in the pathogenesis of splenic diffuse red-pulp small B-cell lymphoma. 12, 28, 31, 32 A second mechanism for lymphomagenesis could relate to chronic stimulation by HBV antigens, thereby leading to incremental proliferation of B-lymphocytes and, consequently, monoclonal malignant expansion. The incremental B-cell proliferation may lead to predisposition towards genetic aberrations, thus promoting neoplastic transformation.
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CONCLUSION
We have described two cases of splenic diffuse red-pulp small B-cell lymphoma associated with HBV. Although we hypothesized that HBV might be implicated in the pathogenesis of this lymphoma, no direct association between these two entities could be proved in this study, and further investigations are necessary.
